X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sonidegib (60) 60
vismodegib (38) 38
index medicus (35) 35
humans (28) 28
basal cell carcinoma (27) 27
oncology (24) 24
open-label (21) 21
cancer (19) 19
pharmacology & pharmacy (18) 18
hedgehog pathway (17) 17
carcinoma, basal cell - drug therapy (15) 15
hedgehog proteins - antagonists & inhibitors (15) 15
multicenter (15) 15
signal transduction - drug effects (14) 14
tumors (14) 14
skin neoplasms - drug therapy (13) 13
basal-cell carcinoma (12) 12
pyridines - therapeutic use (12) 12
hedgehog (11) 11
male (11) 11
pyridines - adverse effects (11) 11
antineoplastic agents - therapeutic use (10) 10
care and treatment (10) 10
clinical trials (10) 10
female (10) 10
metastasis (10) 10
middle aged (10) 10
resistance (10) 10
therapy (10) 10
biphenyl compounds - therapeutic use (9) 9
dermatology (9) 9
double-blind (9) 9
medicine & public health (9) 9
patients (9) 9
phase-ii (9) 9
skin cancer (9) 9
activation (8) 8
adult (8) 8
analysis (8) 8
anilides - therapeutic use (8) 8
antineoplastic agents - adverse effects (8) 8
biphenyl compounds - adverse effects (8) 8
drug therapy (8) 8
review (8) 8
sonic-hedgehog (8) 8
aged (7) 7
efficacy (7) 7
hedgehog pathway inhibitor (7) 7
medulloblastoma (7) 7
mutation (7) 7
mutations (7) 7
smoothened receptor - antagonists & inhibitors (7) 7
solid tumors (7) 7
surgery (7) 7
animals (6) 6
antineoplastic agents - pharmacology (6) 6
carcinoma, basal cell - pathology (6) 6
drug-resistance (6) 6
human homolog (6) 6
inhibitor (6) 6
itraconazole (6) 6
ligands (6) 6
management (6) 6
pharmacology/toxicology (6) 6
research (6) 6
signaling pathway (6) 6
skin neoplasms - pathology (6) 6
smoothened receptor (6) 6
anilides - adverse effects (5) 5
biology (5) 5
bolt (5) 5
cancer therapies (5) 5
cell biology (5) 5
dose-escalation (5) 5
drug dosages (5) 5
growth (5) 5
hedgehog protein (5) 5
hedgehog proteins - metabolism (5) 5
lde225 (5) 5
pharmacology (5) 5
pyridines - pharmacokinetics (5) 5
pyridines - pharmacology (5) 5
sonic hedgehog (5) 5
trial (5) 5
absorption (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
arsenic trioxide (4) 4
biphenyl compounds - administration & dosage (4) 4
biphenyl compounds - pharmacokinetics (4) 4
carcinoma, basal cell - secondary (4) 4
chemotherapy (4) 4
dosage and administration (4) 4
genomic analysis (4) 4
hedgehog signaling pathway (4) 4
locally advanced basal cell carcinoma (4) 4
medical research (4) 4
medicine, experimental (4) 4
neoplasms - drug therapy (4) 4
pathway inhibitor (4) 4
pyridines - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 07/2019, Volume 17, Issue 7, pp. 778 - 784
Clear cell basal cell carcinoma (BCC) is an unusual variant of BCC. Its pathogenesis, prognosis, and optimal management remain poorly described due to its... 
VISMODEGIB | EFFICACY | ONCOLOGY | SAFETY | BOLT | SONIDEGIB | SKIN | STEVIE | TUMORS
Journal Article
Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 11/2018, Volume 145, pp. VS36 - VS41
Until recently, advanced BCC were only accessible to a highly morbid surgery not necessarily proving to be carcinologic, and leaving terrible dysmorphic... 
Sonidegib | Immunotherapy | Advanced BCC | Vismodegib | Hedgehog pathway
Journal Article
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, ISSN 0023-2165, 01/2018, Volume 235, Issue 1, pp. 15 - 22
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 07/2019, Volume 139, Issue 7, pp. 1439 - 1448
Basal cell carcinomas (BCCs) rely on Hedgehog (HH) pathway growth signal amplification by the microtubule-based organelle, the primary cilium. Despite naive... 
ACTIVATION | INHIBITION | VISMODEGIB | PROTEIN | RECURRENT | GENOMIC ANALYSIS | DRUG-RESISTANCE | DIFFERENTIATION | SONIDEGIB | CANCER | DERMATOLOGY
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 61, pp. 104182 - 104192
Purpose: To determine the pharmacodynamic effects of Sonidegib (LDE-225) in prostate tumor tissue from men with high-risk localized prostate cancer, by... 
Clinical trial | Hedgehog | Sonidegib (LDE-225) | GLI1 | Prostate cancer | clinical trial | prostate cancer | GROWTH | ITRACONAZOLE | EXPRESSION | CARCINOMA | CELL BIOLOGY
Journal Article
Development (Cambridge, England), ISSN 0950-1991, 11/2018, Volume 145, Issue 21, p. dev168898
First described in Drosophila, Hedgehog signalling is a key regulator of embryonic development and tissue homeostasis and its dysfunction underlies a variety... 
MEMBRANE-PROTEIN | PATCHED GENE | POLARITY GENE | SONIDEGIB LDE225 | SMOOTHENED GENE | DEVELOPMENTAL BIOLOGY | PHASE-I | SPATIAL-DISTRIBUTION | HUMAN HOMOLOG | SONIC-HEDGEHOG | FUSHI-TARAZU
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 07/2014, Volume 74, Issue 1, pp. 63 - 75
The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. Six... 
ACIDIC DRUGS | Absorption | ONCOLOGY | Distribution | Excretion Hedgehog | PHARMACOLOGY & PHARMACY | Sonidegib (LDE225) | Metabolism | ACCELERATOR MASS-SPECTROMETRY | BINDING | CANCER | HEDGEHOG
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. e755 - e764
The Hedgehog pathway inhibitors (HPIs), vismodegib and sonidegib, are increasingly employed in the treatment of patients with advanced basal cell carcinoma... 
Response | Recurrence | Basal cell carcinoma | Advanced | Sonidegib | Follow‐up | Metastatic | Vismodegib | MULTICENTER | MANAGEMENT | OPEN-LABEL | CHEMOTHERAPY | Follow-up | NONMELANOMA SKIN-CANCER | ONCOLOGY | HIGH-RISK | DOUBLE-BLIND | ADVERSE EVENTS
Journal Article
CELLS, ISSN 2073-4409, 05/2019, Volume 8, Issue 5, p. 394
The Hedgehog/GLI signaling pathway plays an important role in normal embryonic tissue development and has been implicated in the pathogenesis of various human... 
STANDARD CHEMOTHERAPY | sonidegib | GLI factors | vismodegib | OPEN-LABEL | SONIDEGIB LDE225 | DRUG-RESISTANCE | CELL BIOLOGY | DOSE-ESCALATION | Hedgehog | Smoothened | PHASE-II TRIAL | PATHWAY INHIBITOR | BASAL-CELL CARCINOMA | ORAL SMOOTHENED INHIBITOR | DOUBLE-BLIND | clinical trials
Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 9, pp. 2082 - 2091
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with... 
TRIAL | MULTICENTER | ADVANCED SOLID TUMORS | VISMODEGIB | ONCOLOGY | HEDGEHOG PATHWAY INHIBITOR | SONIDEGIB LDE225 | OPEN-LABEL | MECHANISMS | Slopes | Therapy | Toxicity | Muscles | Fatigue | Nausea | Pharmacology | mRNA | Metastasis | Patients | Biological activity | Metastases | Spasms | Confidence intervals | Experimental design | Hedgehog protein | Safety engineering | Skin | Cancer
Journal Article
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, ISSN 0151-9638, 11/2018, Volume 145, pp. 36 - 41
Until recently, advanced BCC were only accessible to a highly morbid surgery not necessarily proving to be carcinologic, and leaving terrible dysmorphic... 
MULTICENTER | Advanced BCC | STEVIE | Hedgehog pathway | DERMATOLOGY | THERAPY | Sonidegib | Immunotherapy | DOUBLE-BLIND | RESISTANCE | Vismodegib | INHIBITOR | HUMAN HOMOLOG
Journal Article